NIH/FDA request for grant applications
This Funding Opportunity Announcement (FOA) encourages Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose to develop new non-animal-based assays to assess the potency of botulinum neurotoxin type A (BoNT/A) in a Good Manufacturing Practice (GMP) commercial environment. Successful projects should have as their goal the development of a test(s) and reagents that could be used for commercial release testing of BoNT/A products.
Budget and Project Period.
Phase I awards normally may not exceed $100,000 total for a period normally not to exceed 1 year. Phase II awards normally may not exceed $750,000 total for a period normally not to exceed 2 years. These award levels and project periods are statutory guidelines, not ceilings. Therefore, applicants are encouraged to propose a budget and project duration period that is reasonable and appropriate for completion of the research project. Phase II Competing Renewal budgets must be submitted in accordance with participating IC-specific budget limitations described in the current SBIR/STTR Program Descriptions and Research Topics of the NIH, CDC and FDA.
Eligible Institutions/Organizations.
Only United States SBCs may submit STTR applications and receive STTR awards.
Key Dates
Release/Posted Date: April 29, 2009
Opening Date: July 5, 2009 (Earliest date an application may be submitted to Grants.gov)
For details see:
http://grants.nih.gov/grants/guide/pa-files/PA-09-178.htmlHorst Spielmann
